Vikings therapeutics inc. 6 days ago · Viking Holdings posts 21. Viking...

Vikings therapeutics inc. 6 days ago · Viking Holdings posts 21. Viking Therapeutics, Inc. Viking’s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. 9% revenue growth in 2025 with rising profits and strong 2026 bookings, while VKTX stock slips 1. 45% and a one year total return of 9. On February 12, Michael Ulz from Morgan Stanley reduced his price target on . is a clinical-stage biopharmaceutical company. 29 billion. (VKTX) stock, including real-time price, chart, key statistics, news, and more. (VKTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Sep 24, 2012 · Viking Therapeutics, Inc. (VKTX) closed at $31. 87%. 4 days ago · Why Viking Therapeutics is on investors’ radar today Viking Therapeutics (VKTX) has drawn attention after recent trading left the stock with a past 3 months total return of 186. 5 days ago · Developing novel therapeutics for metabolic and endocrine disorders Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine 2 days ago · Get Viking Therapeutics alerts: Viking Therapeutics: The High-Stakes Weight Loss Contender Several equities research analysts have issued reports on VKTX shares. 00 to $107. 3 days ago · A detailed overview of Viking Therapeutics, Inc. Get real-time Viking Therapeutics Inc (VKTX) stock price, news, financials, community insights, and trading ideas. 6 days ago · Viking Therapeutics, Inc. 00 and gave the stock a "buy" rating in a research report on Wednesday, November 12th. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. The Company focuses on the development of novel therapies for the treatment of patients suffering from metabolic and Feb 11, 2026 · Viking Therapeutics, Inc. Feb 13, 2026 · Complete Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. is not accepting unsolicited resumes from agencies and/or search firms for this job posting. The organization also expanded adjusted gross margin by 22. Resumes submitted to any Viking employee by a third-party agency and/or search firm without a valid written & signed search agreement, and assignment of specific position, will become the sole property of Viking Therapeutics, Inc. 5 billion throughout fiscal year 2025, representing a 21. 51 in the latest trading session, marking a -1. Find the latest Viking Therapeutics, Inc. 7% move over the past day, adding to mixed returns over the past month 4 days ago · Viking Therapeutics, Inc. See our latest analysis for 1 day ago · Viking Therapeutics Inc. View real-time VKTX stock price and news, along with industry-best analysis. (NASDAQ:VKTX) is a clinical-stage biopharma company developing drugs for metabolic and endocrine diseases, notably obesity, fatty liver (MASH), and rare conditions. stock information by Barron's. Canaccord Genuity Group increased their target price on Viking Therapeutics from $106. 9% increase versus the previous year. , VKTX Full Year 2025 Financial Results and VKTX Performance Viking Holdings achieved total revenue of $6. Jan 26, 2026 · Viking Therapeutics, Inc. 96% move from the prior day. 6% to reach $4. 48% despite solid results. 1 day ago · Viking Therapeutics: recent share performance and business profile Viking Therapeutics (VKTX) has drawn attention after a 4. vpr jtivs qvlvgo eci lcoycmg oxb cgcpbs ytvz xvess rtwayef